BioSante’s Drug for Women’s Sex Drive Spurs Deal-Making Talks, CEO Says
BioSante’s Drug for Women’s Sex Drive Spurs Deal-Making Talks, CEO Says
BioSante Pharmaceuticals Inc. (BPAX) is in talks to partner on its sex gel to raise female libido or sell the company, according to Chief Executive Officer Stephen Simes.
Read more on Bloomberg
Categories: Breast Cancer Information Tags: BioSante’s, DealMaking, Drive, drug, says, Spurs, Talks, Women’s
Patients, scientists at odds over breast cancer drug
Patients, scientists at odds over breast cancer drug
Monday morning, Patricia Howard, 66, was at Memorial Sloan-Kettering Cancer Center in New York, undergoing scans that led doctors to declare her cancer-free — five years after her advanced breast cancer was diagnosed.
Read more on CNN
Categories: Breast Cancer Treatment Tags: breast, cancer, drug, Odds, Over, Patients, Scientists
A Cancer Drug, Avastin, May Lose F.D.A. Approval
A Cancer Drug, Avastin, May Lose F.D.A. Approval
In a series of 6-0 votes, an advisory committee to the F.D.A. endorsed the agency’s proposal to revoke the approval of the drug for use against advanced breast cancer.
Read more on New York Times
Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute …
Lorus Therapeutics Announces Allowance of United States Patent for Cancer Drug LOR-2040 in the Treatment of Acute …
TORONTO, ONTARIO– – Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced that the United States Patent and Trademark Office has allowed a new patent for the Company’s lead clinical stage cancer drug LOR-2040 in the treatment of Acute Myeloid Leukemia .
Read more on CCNMatthews via Yahoo! Finance
Categories: Breast Cancer Information Tags: acute, Allowance, Announces, cancer, drug, LOR2040, Lorus, Patent, States, Therapeutics', Treatment, United
FDA approval for breast cancer drug could be rescinded
Owen Jensen reports: Officials at the Food and Drug Administration have said that their earlier approval of the breast cancer treatment Avastin could soon be revoked in the wake of a report from an advisory committee, which found that the benefits of the drug for many patients are outweighed by its serious side effects.